A San Francisco startup is trying to give your dog one more year — and the FDA just blinked
Doges Editorial · 2026-05-07 · 6 min read
Loyal Inc.'s LOY-002 became the first drug candidate to clear the FDA's "reasonable expectation of effectiveness" threshold for canine longevity — a milestone that puts a daily longevity pill for senior dogs closer to pharmacy shelves than anything that has come before it.
Celine Halioua founded Loyal Inc. in San Francisco in 2019 with a specific, uncomfortable premise: dogs age too fast, we understand a meaningful amount about why, and we have not done nearly enough with that understanding. Seven years later, her company's lead drug candidate — a daily pill called LOY-002 intended for senior dogs over 14 pounds — has crossed a threshold at the FDA that no dog longevity drug has crossed before. The agency has determined there is a "reasonable expectation of effectiveness," which is the regulatory phrase that means the underlying science is credible enough that the next stage of the approval process can proceed. For people who love dogs and have watched them age too quickly, it is the kind of sentence that invites you to read it a second time to confirm it says what you think it says.
What Loyal is building and why the pipeline looks the way it does
Loyal's development pipeline has three products at different stages. LOY-002 is the daily oral pill for senior dogs over 14 pounds — the broadest potential market, the most commercially significant, and the furthest along in the regulatory process. LOY-001 is a veterinarian-administered injectable targeting dogs over 40 pounds, designed for the large-breed population that ages fastest relative to overall lifespan. LOY-003 is a daily oral formulation for dogs over 60 pounds who are at least five years old, addressing the segment at highest risk for the size-correlated aging acceleration that motivates Loyal's science. Each product targets a specific population defined by size and age rather than disease state, which is what makes this longevity medicine rather than conventional veterinary pharmacology.
The company has raised $100 million in a Series C funding round, which has supported both the clinical trial infrastructure and the regulatory engagement that produced the FDA milestone. More than 1,000 dogs are currently enrolled in clinical trials with a five-year follow-up period built into the study design. The projected benefit from LOY-002 is approximately one year of additional healthy lifespan — which, given that one dog year corresponds to roughly five to seven human years depending on the animal's size and current age, represents a genuinely meaningful extension rather than a rounding error.
The FDA milestone and what it actually means
Conditional approval for veterinary drugs in the United States requires three major showings: safety, manufacturing adequacy, and effectiveness. Loyal has now cleared two of the three: the FDA accepted the safety submission and issued the "reasonable expectation of effectiveness" determination, which is based on the mechanistic and early clinical evidence supporting LOY-002's proposed mode of action. Manufacturing standards constitute the remaining requirement before conditional approval can be granted. The conditional approval pathway — created specifically for conditions where the full approval timeline would delay access to treatments that patients, or in this case patients' owners, need — allows veterinarians to prescribe the drug while long-term efficacy data continues to accumulate.
Our products focus on preventative care, addressing the underlying causes of a range of age-associated diseases rather than treating those diseases once they appear.
— Loyal Inc., company statement on the LOY-002 program
The biology behind the size-lifespan relationship
The biological mechanism Loyal is working with relates to the hormonal and metabolic pathways that govern aging rate in dogs — a particularly compelling research area because dogs offer a natural model that other research organisms cannot match. The size-correlated aging difference in dogs is dramatic: a Great Dane's median lifespan is roughly seven to eight years, while a Chihuahua's can exceed fifteen. This variance, across a single species sharing the same basic genome, gives longevity researchers a powerful natural experiment for studying how aging rate is regulated at the molecular level and whether pharmaceutical intervention can shift it. LOY-002 targets the IGF-1 pathway, among other mechanisms, which is implicated in the size-longevity correlation both within dog breeds and in cross-species comparisons.
Halioua has been consistent about the ambition and the constraint simultaneously. The goal is a drug that passes the clinical and regulatory standard — not a supplement that promises longevity without bearing the evidence burden that claim requires. "We're not trying to sell something with sexy marketing," she has said in interviews about the company's approach. "We're trying to build something that actually works, which means it has to go through the same process a human drug would." That commitment to the standard is precisely why the FDA milestone is meaningful: the agency's determination is not a marketing claim. It is a technical evaluation by scientists who are professionally skeptical of longevity claims.
When this becomes something you can give your dog
Conditional approval, if the manufacturing requirement is met, would allow LOY-002 to enter veterinary distribution while long-term trial data continues to accrue. The exact timeline depends on the manufacturing review process and subsequent agency communications. Full approval would follow once the five-year follow-up data matures, is analyzed, and is submitted to the FDA. The path from here to your veterinarian's office is not a straight line, but it is a path with documented progress markers at each stage — which is more than could have been said about canine longevity medicine at any point before this year.
We're not trying to build something with sexy marketing. We're trying to build something that works.
— Celine Halioua, CEO of Loyal Inc.
The emotional weight of this story is not hard to locate. Everyone who has loved a dog has had the experience of watching them age too fast — the gray muzzle that arrives before you expected it, the slower mornings, the stiffness on cold days that becomes the new baseline rather than an exception. Loyal is not promising to prevent those things. It is trying to move the curve: give dogs who are ten years old a better chance at eleven, and make eleven look more like nine than it might otherwise. For a lot of families, that is precisely the thing they would most want someone to be working on. As of April 2026, someone is working on it and the FDA is paying close enough attention to agree the science is sound. What makes the Loyal story unusual among pharmaceutical development narratives is how legible the stakes are to the people most invested in the outcome. Dog owners are not a diffuse constituency with abstract interests in the science. They are people who know exactly how old their dog is, what the breed's typical lifespan looks like, and what the arithmetic would feel like with one more year added to it. That specificity of investment is what has made the ongoing r/dogs threads about Loyal among the most engaged conversations in the subreddit — not because dog owners are naive about the distance from an FDA determination to a pharmacy shelf, but because they understand precisely what is being attempted and why it matters to them personally.